Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with poor prognosis. This study compared patient characteristics, comorbidities, adverse events (AEs), treatment persistence, healthcare resource utilization (HRU) and costs in patients with metastatic MCC (mMCC) treated with imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ying, Yu, Ting, Mackey, Rachel H, Gayle, Julie A, Wassel, Christina L, Phatak, Hemant, Kim, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001053/
https://www.ncbi.nlm.nih.gov/pubmed/33790597
http://dx.doi.org/10.2147/CEOR.S290768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001053/
https://www.ncbi.nlm.nih.gov/pubmed/33790597
http://dx.doi.org/10.2147/CEOR.S290768

Ejemplares similares